Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts

Ryan E. Lawrence*
Department of Psychiatry, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York State Psychiatric Institute, New York, NY, USA
*To whom correspondence should be addressed; 1051 Riverside Drive, New York, NY, 10032, USA; tel: 212-305-0779, e-mail: rel2137@cumc.columbia.edu

Background and Hypothesis: There is limited evidence guiding clinicians and patients on how long to continue antipsychotic medication beyond the first 1–2 years of treatment. Data from long-term (beyond 2 years) placebo-controlled trials would be informative but would be resource-intensive and technically difficult to obtain. Philosophy and history offer perspective on whether schizophrenia researchers should invest in such trials. Study Design: Essay. Results: In Descartes’ model of science, knowledge grows by accumulation and evolves from simpler toward more complex areas. From this perspective, the most important questions are when and how to build this evidence base. In Kuhn's model of science, paradigm shifts can occur that reframe which questions and answers are meaningful. From this perspective, the question of whether to invest in long-term placebo-controlled trials is especially important. An historical review of schizophrenia over the past century indicates that major paradigm shifts have occurred regarding schizophrenia treatments, what counts as evidence, and the definition of schizophrenia. Conclusions: While long-term placebo-controlled trials would add value within the current paradigm, if a paradigm shift occurs there is a risk that this value would not be maintained in the new paradigm.

Key words: antipsychotics/maintenance/treatment/patients/schizophrenia/placebo-controlled trials

Introduction

For decades, psychiatry has wrestled with the question of how long persons with schizophrenia should continue antipsychotic medication (D2 receptor antagonists).1,2 Treatment guidelines from the World Federation of Societies of Biological Psychiatry,3 the National Institute for Health and Care Excellence,4 the Royal Australian and New Zealand College of Psychiatrists,5 and the Canadian Schizophrenia Guidelines6 have generally recommended continuous antipsychotic treatment for at least the first 1–2 years after a psychotic episode or exacerbation, sometimes extending this to 5 years or longer in specific circumstances. However, authors caution that “Recommendations for treatment durations in schizophrenia do not have a strong empirical basis and further studies are needed to provide better evidence-based recommendations” (p. 13).3 also7 Notably, the most recent guidelines from the American Psychiatric Association8 recommend maintenance medication without recommending specific time intervals, instead emphasizing frequent review of the pros and cons in the context of shared decision-making.

The decision of whether to continue antipsychotic medication after a period of stability has significant implications. Continuing antipsychotic medication long-term can involve numerous adverse effects (eg, tardive dyskinesia, Parkinsonism, sedation, weight gain, diabetes), financial burden, inconvenience, and stigma, without necessarily preventing relapse or halting disease progression.9–12 Alternatively, stopping antipsychotic medication can increase the risk of relapse, which may result in hospitalization, unsafe behaviors, personal distress, social/interpersonal disruption, and by some accounts an increased risk of refractory symptoms.13,14 Complicating this decision is an awareness that while antipsychotic medication helps many patients achieve remission or maintain symptom stability (at least with respect to some symptom domains, eg, positive symptoms, disorganization, affective symptoms),15 some patients do well (or as well) without continuous medication,16,17 some remain symptomatic despite continuous medication,18 and there is currently no evidence-based way to predict reliably and
specifically whether a patient belongs to 1 category or another.7

The existing literature is conspicuously lacking double-blind, randomized, placebo-controlled trials to guide treatment decisions beyond the first 2 years.7 Building such an evidence base could have enormous benefit, potentially affecting every patient with schizophrenia at 1 point or another. However, there are important reasons why these studies have not been conducted. The pragmatic challenges are formidable, especially: generating consensus on outcome measures, defining and recruiting a sufficiently homogenous population, establishing and maintaining adherence to a protocol, retaining enough subjects to generate meaningful results, and replicating core findings. Nevertheless, these challenges might be surmountable with sufficient resources and sufficient time.

This essay will focus less on the technical questions surrounding whether psychiatry could meaningfully study antipsychotic maintenance treatment via long-term, double-blind, randomized, placebo-controlled trials. Rather, it will consider the ethical question of whether psychiatry should. To be ethical (and feasible) the benefits must compare favorably against risks and costs. How long the potential benefits will last is an important consideration that has received little attention to date. Will benefits endure, or will schizophrenia research change in ways that render the findings less relevant, harder to apply, or otherwise less beneficial than originally hoped? To develop this question, this essay will look to two contrasting perspectives on science, one proposed by René Descartes and the other by Thomas Kuhn, while looking also to the history of medicine and the history of schizophrenia in particular.

Descartes—Discourse on Method

René Descartes (1596–1650), in his Discourse on the Method of Rightly Conducting the Reason and Seeking for Truth in the Sciences,19 articulated a method that enormously influenced the sciences during subsequent centuries, and which contemporary scientists will recognize as central to the scientific method. In Part II Descartes recommended 4 precepts:

The first of these was to accept nothing as true which I did not clearly recognize to be so... The second was to divide up each of the difficulties which I examined into as many parts as possible... The third was to carry on my reflections in due order, commencing with objects that were the most simple and easy to understand, in order to rise little by little, or by degrees, to knowledge of the most complex... The last was in all cases to make enumerations so complete and reviews so general that I should be certain of having omitted nothing. (p. 13)19

Using this method, Descartes hoped “there can be nothing so remote that we cannot reach to it, nor so reconcile that we cannot discover it” (p. 13).19

Placing the central question (how long to continue antipsychotic medication) within this intellectual tradition gives it a particular framing. The question is readily viewed as a component of the larger moral and scientific question of how best to care for persons with schizophrenia. The question assumes increasing importance as less-complex questions are answered, maybe even taking on an air of inevitability. That the path will be potentially costly and challenging is not necessarily problematic; Descartes’ framework anticipated some steps being more resource intensive than others. Moreover, those who engage in the undertaking, both researchers and subjects, may believe with good reason that their efforts are contributing to an enduring body of knowledge about schizophrenia and its treatment. The central debate, from this perspective, is not whether to invest in this line of research, but how and when.

Kuhn—The Structure of Scientific Revolutions

Thomas Kuhn (1922–1996) proposed a very different view of science, one that challenged the notion that science progresses through the accumulation of facts, theories, and laws. In The Structure of Scientific Revolutions,20 he proposed that each age is dominated by a paradigm. This paradigm organizes a scientific field, indicates which questions are meaningful, and restricts what will count as answers. Adherents, accepting the paradigm and working within it, engage in “normal science,” or a series of puzzle-solving endeavors intended to work out the various implications of the paradigm. Importantly, no paradigm is complete, and normal science eventually produces anomalies (observations that cannot be reconciled with the paradigm). When these anomalies can no longer be ignored there is a crisis and a period of “extraordinary science” during which a new paradigm is forged. This new paradigm is gradually accepted, beginning a new cycle.

In Kuhn’s model, both questions and answers are contingent on the paradigm, and when the paradigm changes, so do the questions and answers that people care about. In contrast to Descartes’ optimism that “there can be nothing so remote that we cannot reach to it, nor so reconcile that we cannot discover it” (p. 13),19 Kuhn’s model predicts that many questions will go forever unanswered; either because the answers are unattainable within the current paradigm (anomalies), or because a paradigm shift occurs before specific puzzles have been solved. Moreover, even when questions are answered there is no guarantee that the answers or indeed the questions themselves will be relevant in the new paradigm.

From this perspective, planning and developing new lines of research—especially research involving complex issues such as how long to continue antipsychotic medication—must consider not only pragmatic questions about how and when, but also the overarching question of whether to pursue this line of research. Kuhn’s model
predicts that not all questions have answers, and not all answers endure.

**Paradigm Shifts: Examples**

The history of schizophrenia in the 20th century has some important examples of paradigm shifts: the introduction of antipsychotic medication, the introduction of randomized controlled trials, and periodic revisions to diagnostic nomenclature. At each transition the questions people asked and the answers they accepted fundamentally changed.

**Introduction of Antipsychotic Medication**

The discovery of antipsychotic medication brought about a paradigm shift in how psychiatrists thought about schizophrenia treatment. In a superficial sense, it is self-evident that psychiatrists did not ask how long to continue antipsychotic medication before there was antipsychotic medication. More deeply, a review of period textbooks captures a fundamental reconceptualization of schizophrenia and its treatment.

*Eugene Bleuler, Textbook of Psychiatry (1924).* Decades before the discovery of antipsychotic medications, in his *Textbook of Psychiatry*, Eugene Bleuler (1857–1939) considered short-term asylum-based treatment to be the core intervention. He believed, “Most schizophrenics are not to be treated at all, or at any rate outside of asylums” (p. 443). Beyond this he claimed, “the supreme remedy … is training for work under conditions that are as normal as possible” (p. 443), as well as providing practical support for individuals living in the community (p. 445).

Bleuler’s textbook mentions only a few instances where medication might be helpful: bromide for “general nervous excitability” and Hyoscine (scopolamine), morphone, and Somnifen (a barbiturate) for feeding malnourished persons (p. 444).

*Wendell Muncie, Psychobiology and Psychiatry: A textbook of Normal and Abnormal Human Behavior, 2nd Edition (1948).* Just a few years before the discovery of chlorpromazine, Wendell Muncie (b. 1897) published his textbook. Muncie was a psychiatrist affiliated with Johns Hopkins University and his textbook carried an endorsement from Adolph Meyer (1886–1950).

Muncie promoted a psychodynamic view of schizophrenia, describing its symptoms as bizarre reactions to stressful circumstances or psychological conflicts. The disease might be precipitated by conflicts involving sexuality, religion, ethics, philosophy, ambitions, life goals, marital adjustment, and the “competitive situation in the struggle for existence” (p. 397). Acute symptoms could become chronic due to “the increasing weight of the habits formed in the acute phase: emotional habits, habits of thinking, management of the instinctual urges” (p. 399). He considered psychodynamic psychotherapy to be the foundation of treatment.

Muncie developed a longer list of medications and indications than what Bleuler presented, describing approximately 10 medications including morphine and alcohol (the latter of which he did not recommend). His concept of what psychiatric medication could do was limited to “reducing tension states, motor unrest, mental turmoil, and insomnia” (p. 533), a conceptualization that was reasonable given the available formulary, but that also relegated medication to a minor or peripheral role in schizophrenia treatment.

*Jack Ewalt and Dana Farnsworth, Textbook of Psychiatry (1963).* In 1963, a decade into the antipsychotic era, Jack Ewalt (1910–1998) and Dana Farnsworth (1905–1986), both Harvard psychiatrists, published a textbook of psychiatry. Their primary orientation was explicitly psychoanalytic, holding that schizophrenia originates from disrupted early relationships, leading the person to respond to later realities with the emotions and thought processes of the infant ego and regression to the state of primary narcissism (p. 213). They framed symptoms of schizophrenia (e.g., delusions, hallucinations, disorganization) as expressions of anxiety or aggression, or as defense against emotional connections with others (p. 214–218).

Importantly, they describe medication as having a major role, but they framed this role as subservient to psychodynamic aims.

…the physician needs a well-organized therapeutic plan. An early decision must be made about the depth and intensity of the psychotherapy: will the goal be to uncover the basic conflict material and aid in development of a stronger ego, or will the goal be social manipulation and ego support? …Ego support and rehabilitation is the basic technique; it should be used with all patients and comes in many forms… The tranquilizing drugs also play a major role in ego support. They seem to be the most effective way of reducing stress so that the patient can cope with his environment without the need to regress into psychotic behavior. Patients who escape from interaction with family, other patients, and personnel through psychotic behavior often respond to ataractic [antipsychotic] drugs by resuming behavior that is reasonably near normal. They can often enter into meaningful therapeutic relationships that are too threatening without the chemical support. (p. 226)

Ewalt and Farnsworth acknowledge debate between psychotherapists and psychopharmacologists about which method yields better outcomes, and attempt to strike a compromise.

There are psychiatrists, and the authors are among them, who believe that intensive, dynamic psychotherapy in conjunction with the ego-supportive methods outlined above
Many researchers who conducted these early trials were explicitly critical of previous research methods and deliberate in forging improved methods. Good et al.27 and Gross28 both conducted their trials because existing evidence was limited to clinical impressions and opinions. Diamond and Marks29 as well as Blackburn and Allen30 conducted their trials in part because of a prior study that had no control group. Caffey et al.31 believed earlier studies had misinterpreted key findings and mishandled study dropouts. Leff and Wing32 expressed multiple criticisms of prior studies, including inherent bias in the design and failing to measure treatment adherence. Hogarty et al.33 and Chouinard et al.34 criticized studies for enrolling diagnostically and prognostically mixed patient groups. Rifkin et al.35 noted that previous studies did not analyze samples with regard to remission status. Andrews et al.36 and Wisted37 provide long lists of methodological limitations in previous literature and propose to overcome them. While some of this might be self-justification, common in scientific writing, there is little question that trials were becoming more rigorous and sophisticated.

It would be fair to debate whether clinical trials methodology has reached maturity, stabilizing around best practices, versus how much it will continue to evolve. However, the lesson from history is that methods of reasoning—what count as compelling justifications—can change. Evidence and arguments that triumph one day can, at a later date, appear far less compelling.

Revisions of Diagnostic Nomenclature
Periodic changes in psychiatric diagnoses have also functioned at the level of a paradigm shift. Michael First,
a leader in the development of multiple editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) credits the original DSM, published in 1952, with introducing a paradigm shift. It standardized a diagnostic vocabulary for a generation of psychiatrists who were less embedded in public mental health hospitals where psychotic illnesses and Kraepelinian models dominated. It also made psychodynamic and psychosocial theories of psychopathology central to diagnosis and treatment.

Decades later the DSM-III, published in 1980, introduced another paradigm shift. It was created in response to criticism that psychiatric diagnoses had poor interrater reliability, and in response to psychiatry’s need to conduct clinical trials evaluating a growing formula of psychiatric medications. It introduced a now-familiar symptom-based approach that equated visible and measurable symptoms with the presence of disease. While it remained theory-neutral regarding etiology, there was hope that it would help psychiatric researchers advance toward greater understanding of etiology and pathophysiology.

When preparations for the DSM-5 began in 1999 there was hope that it would initiate another paradigm shift; introducing a diagnostic system based not on descriptions of symptoms but on etiology and pathophysiology. Unfortunately, early feedback from workgroups indicated there was insufficient understanding of the etiology and pathophysiology of mental disorders to justify replacing the descriptive approach, and that—while the DSM-5 could be groundbreaking in many respects—this particular paradigm shift would have to wait.

While changes in diagnostic criteria can have good reasons behind them, they can also be disruptive to patients, clinicians, and researchers. Psychiatrists studying maintenance treatment in the 1970s complained about how difficult it was to interpret and compare clinical trials that used different diagnostic criteria. Spitzer et al. advised in advance of publication that the DSM-III made several substantive changes to the schizophrenia diagnosis, and that many individuals diagnosed with schizophrenia under DSM-II would receive a different diagnosis in the DSM-III (eg, paranoid disorder, schizoaffective disorder, affective disorder).

It is hard to predict when the next diagnostic paradigm shift will occur, but easy to forecast that research using a new diagnostic paradigm will be difficult to reconcile with the current evidence base. If schizophrenia is redefined as several different disorders, or if biomarkers reveal different subtypes that respond to different treatments, research based on the former diagnostic criteria will appear outdated and potentially irrelevant.

Discussion

Descartes and Kuhn provide contrasting views of science, which generate very different assessments of research proposals involving long-term, double-blind, randomized, placebo-controlled trials of antipsychotic medication in schizophrenia. From Descartes’ perspective, moving into this line of research—or at least seriously considering it—would be appropriate, desirable, and maybe inevitable. Many less-complicated questions have already been addressed by short-term acute treatment trials and longer-term relapse prevention trials. At some point, conducting even longer clinical trials to inform antipsychotic treatment beyond 2 years would become the next priority (assuming the trials are feasible).

Alternatively, Kuhn’s observation that science undergoes paradigm shifts, during which questions and answers both change, suggests grounds for caution. Paradigm shifts have happened in psychiatry. A clinical trial that would span many years, would be resource intensive, and would be technically difficult seems especially vulnerable to disruption from a paradigm shift. It is not hard to imagine scientific advances that would initiate a paradigm shift in schizophrenia: effective preventative measures, biomarkers that distinguish different kinds of psychotic illnesses, predictors of antipsychotic response and non-response, pharmacotherapies with new mechanisms of action, targeted brain stimulation techniques, and agents with disease modifying potential are a few examples. Paradoxically, the more optimistic psychiatrists are about any of these breakthroughs happening soon, the more cautious they should be about embarking on a long, costly, and difficult clinical trial studying antipsychotic maintenance treatment.

The potential for a paradigm shift to diminish or truncate the benefits derived from these studies should be a consideration for researchers, funding agencies, and ethical review boards. In their essay, “What makes clinical research ethical?,” Emanuel et al. list 7 requirements. Three of them—value, scientific validity, favorable risk-benefit ratio—are potentially paradigm specific and subject to change when a paradigm shift occurs. While researchers, funders, and ethical review boards cannot be expected to forecast paradigm shifts with specificity, or to predict the future state, it would be reasonable to ask them to identify and remain cognizant of “anomalies” (Kuhn’s term for observations not easily reconciled with the paradigm) or areas with high potential for change or disruption. The potential for paradigm shift could then be explicitly considered as projects examining these areas are designed and reviewed.

The position taken in this essay, which is both cautious and optimistic, has limitations that require several acknowledgements. The current paradigm remains alive and well and it is likely that meaningful discoveries will still be made within this paradigm. When paradigms shift, there are elements of continuity that persist, such that not everything is discarded with the old paradigm (although predicting what will translate into the new paradigm and what place it will hold can be difficult). Perpetually
waiting for paradigms to shift before embarking on research initiatives would greatly limit discovery within the current paradigm, and would halt the process of evolving toward the next paradigm. Concerns for a paradigm shift might appear misplaced in hindsight if new developments take many years or decades to materialize; meanwhile, patients and clinicians rely on suboptimal evidence to make important treatment decisions.

Conclusion
There is no question that psychiatry would benefit from successful long-term, double-blind, randomized, placebo-controlled trials to inform clinical decisions about how long to continue antipsychotic medication. The question is how long the benefits would endure, and whether the benefits would justify the costs and risks associated with such trials. Paradigm shifts in schizophrenia have occurred, changing both the questions and the answers that people care about. While it would not be wise to move forward with considering these trials, stakeholders should remain aware that data generated today may not be as meaningful tomorrow. In weighing all of the considerations mentioned above, it seems unlikely that the benefits will be worth the investment.

Conflict of Interest
The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References
1. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry. 1975;132(12):1237–1245.
2. Gardos G, Cole JO. Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry. 1976;133(1):32–36.
3. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.
4. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg178.
5. Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):1–117.
6. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616.
7. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160.
8. American Psychiatric Association. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd ed. Washington, DC: American Psychiatric Association; 2021.
9. Barlati S, Morena D, Nibbio G, et al. Internalized stigma among people with schizophrenia: relationship with sociodemographic, clinical and medication-related features. Schizophr Res. 2022;243:364–371.
10. Harrow M, Jobe T, Tong L. Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders (online ahead of print on February 8, 2021). Psychol Med. doi:10.1017/S0144615X20004778.
11. Howes OH, Kaar SJ. Antipsychotic drugs: challenges and future directions. World Psychiatry. 2018;17(2):170–171.
12. Rubio JM, Schoretssanitis G, John M, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749–761.
13. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–121.
14. Emsley R, Fleischhacker WW, Galderisi S, Halpern LJ, McEvoy JP, Schooler NR. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. BMJ. 2016;354:i4728.
15. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;16(5):CD008016.
16. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry. 2005;50:892–900.
17. Wunderink L, Nieboer RM, Wiersma D, Sytens M, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–920.
18. Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021;82(5):MY20096AH–MY200961CC.
19. Descartes R. Discourse on Method and Meditations on First Philosophy. New Haven, CT: Yale University Press and Vail-Ballou Press; 1637/1996.
20. Kuhn TS. The Structure of Scientific Revolutions, 4th ed. Chicago, IL: The University of Chicago Press; 1962/2012.
21. Bleuler E. Textbook of Psychiatry. New York: The MacMillan Company; 1924.
22. Muncie W. Psychobiology and Psychiatry: A Textbook of Normal and Abnormal Human Behavior, 2nd ed. St. Louis, MO: The C.V. Mosby Company; 1948.
23. Ewalt JR, Farnsworth DL. Textbook of Psychiatry. New York, NY: McGraw-Hill Book Company, Inc.; 1963.
24. Freedman AM, Kaplan HI, Sadock BJ. Modern Synopsis of Comprehensive Textbook of Psychiatry. Baltimore, MD: The Williams & Wilkins Co.; 1972.
25. Matthews JR. Quantification and the Quest for Medical Certainty. Princeton, NJ: Princeton University Press; 1995.
26. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–782.
27. Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenia patients. Am J Psychiatry. 1958;115:443–448.
28. Gross M. The impact of ataractic drugs on a mental hospital outpatient clinic. *Am J Psychiatry*. 1960;117:444–447.
29. Diamond LS, Marks JB. Discontinuance of tranquilizers among chronic schizophrenia patients receiving maintenance dosage. *J Nerv Ment Dis*. 1960;131:247–251.
30. Blackburn HL, Allen JL. Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics. *J Nerv Ment Dis*. 1961;133:303–308.
31. Caffey EM, Diamond LS, Frank TV, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. *J Chronic Dis*. 1964;17:347–358.
32. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. *Br Med J*. 1971;3(5775):599–604.
33. Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. *Arch Gen Psychiatry*. 1973;28(1):54–64.
34. Chouinard G, Annable L, Serrano M, Albert JM, Charette R. Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction. *Arch Gen Psychiatry*. 1975;32(10):1295–1307.
35. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. *Arch Gen Psychiatry*. 1977;34(1):43–47.
36. Andrews P, Hall JN, Snaith RP. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. *Br J Psychiatry*. 1976;128:451–455.
37. Wistedt BA. depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. *Acta Psychiatr Scand*. 1981;64(1):65–84.
38. First MB. Paradigm shifts and the development of the Diagnostic and Statistical Manual of Mental Disorders: past experiences and future aspirations. *Can J Psychiatry*. 2010;55(11):692–700.
39. Spitzer RL, Andreasen NC, Endicott J. Schizophrenia and other psychotic disorders in DSM-III. *Schizophr Bull*. 1978;4(4):489–509.
40. Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry*. 2017;174(10):927–942.
41. Lawrence RE, Appelbaum PS, Lieberman JA. A historical review of placebo-controlled, relapse prevention trials in schizophrenia: the loss of clinical equipoise. *Schizophr Res*. 2021;229:122–131.
42. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? *JAMA*. 2000;283(20):2701–2711.